FDA Approves Revolutionary Device to Stop Life-Threatening Bleeding in Seconds

The Food and Drug Administration (FDA) has approved a groundbreaking medical device, Traumagel, that can halt severe bleeding in mere seconds. Developed by Cresilon, Traumagel utilizes a plant-based hemostatic gel technology to stop bleeding from injuries as severe as gunshot wounds.

Traumagel is a pre-filled syringe that is easy to apply, requires no preparation, and is designed to work across all types of bleeds. This innovative device addresses the limitations of existing options like hemostatic agents and gauze bandages, which can be difficult to apply and may not treat all types of bleeds.

According to Cresilon, the ability to rapidly stop bleeding at the point of care can be the difference between life and death for individuals with traumatic wounds. The company's CEO and co-founder, Joe Landolina, hailed the FDA clearance as a "monumental milestone" in their mission to save lives and transform wound treatment.

Traumagel's proprietary hemostatic gel technology has the potential to revolutionize the standard of care in wound treatment. With the ability to stop severe bleeding in minutes, this device can help prevent unnecessary deaths. Cresilon plans to launch Traumagel in late 2024.